Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Par Megace ES approved

Executive Summary

FDA clears Par's appetite stimulant Megace ES July 5 for the treatment of anorexia, cachexia or an unexplained significant weight loss in AIDS patients. The company filed an NDA for the concentrated form of megestrol acetate oral suspension under the 505(b)(2) pathway in June 2004. The product will be launched the week of July 11 through a 59-member sales force. Megace ES is Par's first branded product approval. Megace ES will carry a wholesale acquisition cost of $390 and an average wholesale price of $487 for a one-month supply, Par said...
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS046053

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel